ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,594.66
      0.73%
      US Tech 100
      18,880.40
      0.72%
      Dow Jones
      41,018.30
      0.38%
      Brent Oil
      71.955
      2.03%
      Bitcoin
      58,265.10
      1.60%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Iterum Therapeutics PLC (ITRM)

      7. Iterum Therapeutics PLC (ITRM) News

      ITRM

      Iterum Therapeutics (ITRM)

      Iterum Therapeutics PLC
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:ITRM
      DateTimeSourceHeadlineSymbolCompany
      09/11/20244:50PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ITRMIterum Therapeutics PLC
      09/10/20247:00AMGlobeNewswire Inc.Iterum Therapeutics Provides Update on FDA Advisory Committee Discussion of Oral Sulopenem for the Treatment of uUTI in Adult WomenNASDAQ:ITRMIterum Therapeutics PLC
      09/09/20246:15AMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ITRMIterum Therapeutics PLC
      09/06/20244:30PMGlobeNewswire Inc.Iterum Therapeutics to Present at the 26th Annual H.C. Wainwright Global Investment ConferenceNASDAQ:ITRMIterum Therapeutics PLC
      08/14/20244:15PMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ITRMIterum Therapeutics PLC
      08/14/20247:30AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ITRMIterum Therapeutics PLC
      08/14/20247:15AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
      08/14/20247:00AMGlobeNewswire Inc.Iterum Therapeutics Reports Second Quarter 2024 Financial ResultsNASDAQ:ITRMIterum Therapeutics PLC
      08/14/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ITRMIterum Therapeutics PLC
      08/09/20245:28PMEdgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:ITRMIterum Therapeutics PLC
      08/07/20244:30PMGlobeNewswire Inc.Iterum Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024NASDAQ:ITRMIterum Therapeutics PLC
      08/06/20245:30PMGlobeNewswire Inc.Iterum Therapeutics Announces Expiration and Results of Rights OfferingNASDAQ:ITRMIterum Therapeutics PLC
      08/06/20245:25PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
      08/02/20244:30PMEdgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ITRMIterum Therapeutics PLC
      08/02/20248:00AMGlobeNewswire Inc.Iterum Therapeutics Broadens Patent Estate for Oral SulopenemNASDAQ:ITRMIterum Therapeutics PLC
      07/22/20248:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
      07/22/20247:30AMGlobeNewswire Inc.Iterum Therapeutics Commences Rights OfferingNASDAQ:ITRMIterum Therapeutics PLC
      07/22/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ITRMIterum Therapeutics PLC
      07/19/20245:05PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ITRMIterum Therapeutics PLC
      07/17/20244:21PMEdgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:ITRMIterum Therapeutics PLC
      06/21/20248:00AMGlobeNewswire Inc.Iterum Therapeutics Announces FDA Advisory Committee Meeting to discuss NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract InfectionsNASDAQ:ITRMIterum Therapeutics PLC
      06/07/20244:11PMEdgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:ITRMIterum Therapeutics PLC
      06/05/20248:00AMGlobeNewswire Inc.Iterum Therapeutics to Present Data at ASM Microbe 2024NASDAQ:ITRMIterum Therapeutics PLC
      05/31/20248:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
      05/31/20248:00AMGlobeNewswire Inc.Iterum Therapeutics Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract InfectionsNASDAQ:ITRMIterum Therapeutics PLC
      05/13/20247:30AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ITRMIterum Therapeutics PLC
      05/13/20247:15AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
      05/13/20247:00AMGlobeNewswire Inc.Iterum Therapeutics Reports First Quarter 2024 Financial ResultsNASDAQ:ITRMIterum Therapeutics PLC
      05/06/20248:00AMGlobeNewswire Inc.Iterum Therapeutics to Report First Quarter 2024 Financial Results on May 13, 2024NASDAQ:ITRMIterum Therapeutics PLC
      04/29/20248:00AMGlobeNewswire Inc.Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral SulopenemNASDAQ:ITRMIterum Therapeutics PLC
       Showing the most relevant articles for your search:NASDAQ:ITRM